Ultrasonographic Assessment of Gastric Residual Volume

June 15, 2020 updated by: Gurhan Taskin

Does Ultrasonographic Assessment of Gastric Antrum Correlate With Gastric Residual Volume in Critically Ill Patients? A Prospective Study

A recent systematic review reported that the prevalence of enteral nutrition intolerance in critically ill patients ranged from 2% to 75%, and the pooled rate was 38.3%.Many randomized controlled trials have reported that the incidence of pneumonia, regurgitation and aspiration do not correlate well with gastric residual volume (GRV) monitoring. In addition, it was reported that GRV monitoring may cause more frequent obstructions in the enteral tube access, leading to greater loss of time for intensive care unit nurses and patients receiving less than the prescribed daily intake due to enteral nutrition interruptions. The most recent SCCM/ASPEN guidelines in 2016 recommended that GRV monitoring not be included in the daily care protocol, but many institutions still use it to determine whether to continue enteral nutrition or to detect enteral tube-feeding intolerance. This study aimed to evaluate the relationship between ultrasonographic gastric antral measurements and aspirated gastric residual volume GRV in mechanically ventilated critically ill patients receiving enteral tube feeding via nasogastric, orogastric, or percutaneous gastrostomy tubes.

Study Overview

Status

Completed

Detailed Description

Data collection and measurements:

The following clinical parameters of included patients will be recorded: age, sex, body weight, height, body mass index, Acute Physiology and Chronic Health Evaluation II (APACHE II) score on the day of admission,the Charlson Comorbidity Index score, any comorbid diseases, the total amount of EN product during the last 24 hours before ultrasonographic assessment, vasopressor therapy during imaging, and the dose of the vasopressors.

Ultrasonographic gastric antrum imaging procedure:

Ultrasonographic gastric antrum imaging will be carried out by the same intensivist on each patient just before routine tube-feed aspiration. Gastric antrum images will be obtained with a 2.5-6 MHz curvilinear probe placed in the sagittal plane of the epigastric region. All imaging attempts will be carried out in a 30-degree head-elevation supine position as described previously. Reference points will be used to obtain images of the gastric antrum-left anterior lobe of the liver, head of pancreas and abdominal aorta.The anteroposterior and craniocaudal diameters of the gastric antrum will be measured three times for each ultrasonographic assessment. The mean value of the three will be recorded. The universally accepted Two-Diameter Method defined by Bolondi et al. will be used for the measurement of antral cross-sectional area.

Tube-feeding aspiration (GRV measurement) procedure:

Routine gastric residual volume aspirations will be performed by the nursing staff blinded to the ultrasonographic measurements. The time between gastric antrum imaging and the beginning of GRV aspiration will be recorded in minutes. Gastric contents will slowly aspirated with 50 ml syringes for at least 10 minutes until stomach contents could no longer be aspirated. Patients will be reassessed with ultrasonography after the aspiration to ensure that the stomach is completely emptied with aspiration.

Study Type

Observational

Enrollment (Actual)

56

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Trabzon, Turkey, 61250
        • University of Health Sciences, Trabzon Kanuni Training and Research Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 100 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Mechanically ventilated critically ill patients receiving enteral feeding via nasogastric, orogastric, or percutaneous gastrostomy tubes who admitted to ICU in a one year period

Description

Inclusion Criteria:

  • 18 years of age or older
  • Mechanically ventilated in the intensive care unit
  • Receiving enteral tube feeding via nasogastric, orogastric, or percutaneous gastrostomy tubes, and the tip of the enteral feeding-tube having been shown to be present in the stomach in a recent x-ray

Exclusion Criteria:

  • Pregnancy
  • Intestinal obstruction, gastric perforation, known upper gastrointestinal anatomical problem (e.g., hiatal hernia, gastric cancer, etc.)
  • Food and liquid by mouth being withheld due to long-term fasting requirement for any medical reasons (e.g., gastrointestinal tract bleeding, etc.)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Study group
Unselected critically ill patients who met the inclusion criteria

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Correlation between antral cross-sectional area and enteral tube feeding volumes.
Time Frame: From date of inclusion until the date of enteral tube-feeding termination or until the date of weaning from mechanical ventilation or until the date of discharging from ICU or until the date of the death, whichever came first, assessed up to one month.
The correlation between aspirated tube-feeding volumes and ultrasonographic gastric antral cross-sectional area measurements in critically ill patients receiving enteral tube feeding.
From date of inclusion until the date of enteral tube-feeding termination or until the date of weaning from mechanical ventilation or until the date of discharging from ICU or until the date of the death, whichever came first, assessed up to one month.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Gurhan Taskin, MD, Gulhane School of Medicine

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 1, 2018

Primary Completion (ACTUAL)

January 19, 2019

Study Completion (ACTUAL)

January 19, 2019

Study Registration Dates

First Submitted

May 23, 2020

First Submitted That Met QC Criteria

May 28, 2020

First Posted (ACTUAL)

June 4, 2020

Study Record Updates

Last Update Posted (ACTUAL)

June 17, 2020

Last Update Submitted That Met QC Criteria

June 15, 2020

Last Verified

June 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

All individual patient data that underlie results in a publication

IPD Sharing Time Frame

Starting 6 months after publication

IPD Sharing Access Criteria

If requested the individual patient data will be shared.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Critically Ill

3
Subscribe